Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

151
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
151
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

940
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
940
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

275
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
275
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

316
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
316

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ritonavir release from spherical amorphous solid dispersions: prediction and observation.

International journal of pharmaceutics·2026
Same author

Impact of gastric mixing and water intake on postprandial pharmacokinetics of orally disintegrating tablets: A PBBM-based study.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2026
Same author

Predicting surfactant effects on drug permeation across hollow fiber membrane.

Journal of pharmaceutical sciences·2026
Same author

Mastering particle size analysis: lessons, challenges, and future directions from the FDA-CRCG workshop.

AAPS open·2026
Same author

Transient pH film model for in vitro powder dissolution of weakly basic drugs into buffer and comparison to conventional film model.

Journal of pharmaceutical sciences·2026
Same author

Reduced-Resistances Model for Enhanced Drug Permeation via a Solubilizing Receiver Medium: A Mechanistic Study with Hollow Fiber Membranes.

Molecular pharmaceutics·2026

Related Experiment Video

Updated: Jun 16, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

17.8K

Biowaiver monograph for immediate-release solid oral dosage forms: Raltegravir potassium.

Atsushi Kambayashi1, Masaki Iida1, Makoto Ishihara1

  • 1Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Japan.

Journal of Pharmaceutical Sciences
|August 18, 2024
PubMed
Summary

Biopharmaceutics Classification System (BCS)-based biowaivers are not recommended for raltegravir potassium immediate-release products due to its solubility and permeability characteristics. This guidance applies to new generics and products with significant formulation or manufacturing changes.

Keywords:
AbsorptionBioavailabilityBioequivalenceBiopharmaceutics classification system (BCS)BiowaiverDissolutionPermeabilityRaltegravir potassiumSolubility

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

480
Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.3K

Related Experiment Videos

Last Updated: Jun 16, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

17.8K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

480
Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.3K

Area of Science:

  • Pharmaceutical Sciences
  • Drug Development
  • Regulatory Science

Background:

  • Raltegravir potassium is an antiretroviral medication used to treat human immunodeficiency virus (HIV) infections.
  • The Biopharmaceutics Classification System (BCS) categorizes drugs based on solubility and permeability to guide regulatory decisions.
  • Biopharmaceutics Classification System (BCS)-based biowaivers can streamline the approval process for certain pharmaceutical products.

Purpose of the Study:

  • To evaluate the suitability of Biopharmaceutics Classification System (BCS)-based biowaivers for immediate-release raltegravir potassium products.
  • To assess the implications of raltegravir potassium's physicochemical properties on biowaiver applicability.
  • To provide guidance on regulatory pathways for raltegravir potassium formulations according to ICH M9.

Main Methods:

  • Physicochemical characterization of raltegravir potassium, focusing on solubility and permeability.
  • Classification of raltegravir potassium within the Biopharmaceutics Classification System (BCS).
  • Review of International Council for Harmonisation (ICH) M9 guidelines regarding biowaivers for immediate-release solid dosage forms.

Main Results:

  • Raltegravir potassium exhibits low solubility and uncertain permeability, suggesting classification under Biopharmaceutics Classification System (BCS) Class II or IV.
  • The International Council for Harmonisation (ICH) M9 guideline advises against Biopharmaceutics Classification System (BCS)-based biowaivers for drugs with these characteristics.
  • The findings indicate that biowaivers are not appropriate for immediate-release raltegravir potassium products.

Conclusions:

  • Biopharmaceutics Classification System (BCS)-based biowaivers are not recommended for immediate-release raltegravir potassium formulations.
  • Regulatory approval for new generic versions or modified raltegravir potassium products should not rely on biowaivers.
  • Adherence to established regulatory guidelines is crucial for ensuring the quality and efficacy of antiretroviral therapies.